Lamzede (Velmanase Alfa)

Velmanase alfa is a recombinant form of human alpha‑mannosidase. After intravenous administration, it is taken up by cells and delivered to lysosomes, where it restores the breakdown of mannose‑rich oligosaccharides, correcting the metabolic defect underlying alpha‑mannosidosis.

The dosing regimen for Lamzede is individualized and determined by the prescribing physician based on the patient’s weight, disease severity, and clinical response. Specific dosing instructions are provided in the product’s prescribing information.

The safety of Lamzede in pregnancy or while breastfeeding has not been fully established. Clinicians should weigh the potential benefits against any unknown risks and consider alternative therapies when appropriate.

To order Lamzede, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Lamzede is a recombinant enzyme replacement therapy that directly supplies the missing alpha‑mannosidase. Alternative approaches may include supportive care or experimental gene therapies, but Lamzede uniquely addresses the enzymatic deficiency through intravenous administration.

Lamzede should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Maintain the cold chain during transport and handling to preserve product stability.

Lamzede is given as an intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the prescriber and may be adjusted based on patient tolerance.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, serum‑sickness‑like events, and pulmonary edema. Patients should be monitored closely during and after infusion for any signs of these reactions.

Lamzede should not be used in individuals with a known severe allergy to the product or its components, or in patients with uncontrolled severe infections. Clinicians should evaluate each patient’s medical history before initiating therapy.